SF1 and neoplasm: As expected, CAM5.2 immunopositive fibrous bodies were highly abundant in SGST-PIT1 (median 90% of tumor cells, compared to 3% in DGST-PIT1/SF1 and 25% in DGST-PIT1, p < 0.001; Fig. 2a, e–g), whereas DGST-PIT1/SF1 and DGST-PIT1 displayed more prominent cytoplasmic CAM5.2 immunoreactivity (median 70% and 50%, respectively, compared to 0% in SGST-PIT1; p < 0.001 ***; Fig. 2b, e–g).